Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

Fig. 2

a Scatter plot on cost-effectiveness plane. b Cost-effectiveness acceptable curve. *Footnote of Figure2: These are results of probabilistic sensitivity analysis based on the bootstrap method. This scatter plot shows the joint distribution of incremental cost and effectiveness. Cost-effectiveness acceptable curve represents the relation between willingness to pay (or threshold) and the probability that S-1 is cost-effective

Back to article page